Core Insights - The stock of Jinghua Pharmaceutical experienced a decline of 0.40% on September 17, with a trading volume of 64.30 million yuan [1] - As of September 17, the company had a total margin balance of 180 million yuan, with a financing net buy of -1.63 million yuan for the day [1][2] - The company reported a revenue of 731 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.54%, while the net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2][3] Financing and Margin Data - On September 17, Jinghua Pharmaceutical had a financing buy of 7.10 million yuan and a financing repayment of 7.26 million yuan, resulting in a net financing buy of -0.16 million yuan [1] - The current financing balance of 180 million yuan accounts for 2.94% of the circulating market value, which is above the 70th percentile of the past year [1] - The company had a margin balance of 28,500 yuan with a remaining short position of 3,800 shares, indicating a low level of short selling activity [1] Shareholder and Dividend Information - As of June 30, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period [2] - The company has distributed a total of 533 million yuan in dividends since its A-share listing, with 205 million yuan distributed in the last three years [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares, and a new entry from the Traditional Chinese Medicine ETF [3]